Cargando…
Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity
BACKGROUND: Castration-resistant prostate cancer (CRPC) is the lethal phenotype of prostate cancer. Lipocalin 2 (LCN2) is aberrantly expressed in many cancers including primary prostate cancer (PCa), but its role in CRPC has not been reported. RESULTS: LCN2 expression was upregulated in human primar...
Autores principales: | Ding, Guanxiong, Wang, Jianqing, Feng, Chenchen, Jiang, Haowen, Xu, Jianfeng, Ding, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325444/ https://www.ncbi.nlm.nih.gov/pubmed/27602760 http://dx.doi.org/10.18632/oncotarget.11790 |
Ejemplares similares
-
Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019) -
Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status
por: Xu, Zhengquan, et al.
Publicado: (2021) -
Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012) -
Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011) -
Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer
por: Myung, Jae-Kyung, et al.
Publicado: (2017)